Listing Regulation Archives

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

22.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 22, 2026 at 16:00:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)

1. Identity of the issuer: FARON PHARMACEUTICALS OY
2. Reason for the notification (please tick the appropriate box or boxes): ☐ An acquisition or disposal of shares or voting rights ☒ An acquisition or disposal of financial instruments ☐ An event changing the breakdown of shares or voting rights ☐ Other (please specify): Click here to enter text.
3. Details of person subject to the notification obligation:
Name: Bank of America Corporation		City and country of residence: Wilmington, DE, United States of America
4. Full name of shareholder(s) (if different from 3.): –
5. Date on which the threshold was crossed or reached: 17.6.2026
6. Total positions of person(s) subject to the notification obligation:
	% of shares and voting rights (total of 7.A)		% of shares and voting rights through financial instruments (total of 7.B)	Total of both in % (7.A + 7.B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	0.17		8.73	8.90	227,881,315
Position of previous notification (if applicable)	0.12		9.99	10.11

7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of shares ISIN code (if possible)		Number of shares and voting rights				% of shares and voting rights
		Direct (SMA 9:5)		Indirect (SMA 9:6 and 9:7)		Direct (SMA 9:5)		Indirect (SMA 9:6 and 9:7)
FI4000153309		0		377,478		0		0.17
–		–		–		–		–
–		–		–		–		–
SUBTOTAL A		377,478				0.17

B: Financial Instruments according to SMA 9:6a
Type of financial instrument	Expiration date		Exercise/ Conversion Period		Physical or cash settlement		Number of shares and voting rights		% of shares and voting rights
Rights of Use	n/a		n/a		n/a		19,584,472		8.59
swaps		15/10/2027		n/a	Cash		314,746		0.14
–	–		–		–		–		–
					SUBTOTAL B		19,899,218		8.73

8. Information in relation to the person subject to the notification obligation (please tick the applicable box): ☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. ☒ Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name	% of shares and voting rights	% of shares and voting rights through financial instruments	Total of both
Bank of America Corporation
NB Holdings Corporation
BofAML Jersey Holdings Limited
BofAML EMEA Holdings 2 Limited
ML UK Capital Holdings Limited
Merrill Lynch International
Bank of America Corporation
NB Holdings Corporation
BAC North America Holding Company
Bank of America, National Association
Bank of America Corporation
NB Holding Corporation
Bofa Securities, Inc		8.59%	8.59%

9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date.

10. Additional information: –

Done at London, United Kingdom on 18.6.2026.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

17.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 16:30:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ:			Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						x
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						x
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights						x
Other (please specify) ⁱⁱⁱ:
3. Details of person subject to the notification obligation ^iv
Name			Timo Syrjälä
City and country of registered office (if applicable)			Monaco
4. Full name of shareholder(s) (if different from 3.) ^v
Name			Acme Investments SPF Sarl
City and country of registered office (if applicable)			Luxembourg
5. Date on which the threshold was crossed or reached ^vi:			11.6.2026
6. Date on which issuer notified (DD/MM/YYYY):			16.6.2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) ^vii
Resulting situation on the date on which threshold was crossed or reached	6.46%				14.712.470
Position of previous notification (if applicable)	7.77%				15.509.443

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ^ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
FI4000153309		5.544.672		9.167.798			2.43%		4.02%


SUBTOTAL 8. A		14.712.470					6.46%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date ^x	Exercise/ Conversion Period ^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date ^x		Exercise/ Conversion Period ^xi		Physical or cash Settlement ^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^xiv				X
Name ^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Timo Syrjälä (Direct)	2.43%		2.43%
Acme Investments SPF Sarl (Indirect)	4.02%		4.02%




10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information Faron has changed 11.6.2026 the way the flagging responsibility is defined by calculating also shares registered and issued to Faron and still owned by company itself. However, shares owned by Faron itself cannot be calculated as capable to vote in shareholders meetings. New total number of Faron shares registered 227.881.315.

Place of completion	Monaco
Date of completion	16.6.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

17.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 09:00:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)

1. Identity of the issuer: FARON PHARMACEUTICALS OY
2. Reason for the notification (please tick the appropriate box or boxes): ☐ An acquisition or disposal of shares or voting rights ☒ An acquisition or disposal of financial instruments ☐ An event changing the breakdown of shares or voting rights ☐ Other (please specify): Click here to enter text.
3. Details of person subject to the notification obligation:
Name: Bank of America Corporation		City and country of residence: Wilmington, DE, United States of America
4. Full name of shareholder(s) (if different from 3.): –
5. Date on which the threshold was crossed or reached: 12.6.2026
6. Total positions of person(s) subject to the notification obligation:
	% of shares and voting rights (total of 7.A)		% of shares and voting rights through financial instruments (total of 7.B)	Total of both in % (7.A + 7.B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	0.12		9.99	10.11	206,411,888
Position of previous notification (if applicable)	0.13		10.07	10.20

7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of shares ISIN code (if possible)		Number of shares and voting rights				% of shares and voting rights
		Direct (SMA 9:5)		Indirect (SMA 9:6 and 9:7)		Direct (SMA 9:5)		Indirect (SMA 9:6 and 9:7)
FI4000153309		0		246,335		0		0.12
–		–		–		–		–
–		–		–		–		–
SUBTOTAL A		246,335				0.12

B: Financial Instruments according to SMA 9:6a
Type of financial instrument	Expiration date		Exercise/ Conversion Period		Physical or cash settlement		Number of shares and voting rights		% of shares and voting rights
Rights of Use	n/a		n/a		n/a		20,374,993		9.87
Swaps		15/10/2027		n/a	Cash		245,294		0.12
–	–		–		–		–		–
					SUBTOTAL B		20,620,287		9.99

8. Information in relation to the person subject to the notification obligation (please tick the applicable box): ☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. ☒ Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name	% of shares and voting rights	% of shares and voting rights through financial instruments	Total of both
–	–	–	–
–	–	–	–
–	–	–	–
–	–	–	–
–	–	–	–

9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date.

10. Additional information:

Done at London, United Kingdom on 15.6.2026.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

15.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 15, 2026 at 18:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ:			Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) ⁱⁱⁱ:
3. Details of person subject to the notification obligation ^iv
Name			Heights Capital Management, Inc.
City and country of registered office (if applicable)			San Francisco, California
4. Full name of shareholder(s) (if different from 3.) ^v
Name			CVI Investments, Inc.
City and country of registered office (if applicable)			Cayman Islands
5. Date on which the threshold was crossed or reached ^vi:			11/06/2026
6. Date on which issuer notified (DD/MM/YYYY):			12/06/2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) ^vii
Resulting situation on the date on which threshold was crossed or reached	8.88%	12.53%		21.41%	48,784,893
Position of previous notification (if applicable)	10.33%	13.84%		24.17%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ^ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
FI4000153309		20,224,893		28,560,000			8.88%		12.53%


SUBTOTAL 8. A		48,784,893					21,41%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date ^x	Exercise/ Conversion Period ^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
Convertible Bond		08/02/2027	Anytime until maturity			11,760,000			5.16%
Convertible Bond		12/02/2028	Anytime until maturity			16,800,000			7.37%

			SUBTOTAL 8. B 1			28,560,000			12.53%

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date ^x		Exercise/ Conversion Period ^xi		Physical or cash Settlement ^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^xiv
Name ^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc.	8.88%	12.53%	21.41%
CVI Investments, Inc.	8.88%	12.53%	21.41%




10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information ^xvi
None

Place of completion	London, United Kingdom
Date of completion	12.06.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

11.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 11, 2026 at 17:05:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ:			Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) ⁱⁱⁱ: Issue of Treasury Shares to the Issuer						X
3. Details of person subject to the notification obligation ^iv
Name			Faron Pharmaceuticals Ltd
City and country of registered office (if applicable)			Turku, Finland
4. Full name of shareholder(s) (if different from 3.) ^v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached ^vi:			11.6.2026
6. Date on which issuer notified (DD/MM/YYYY):			11.6.2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) ^vii
Resulting situation on the date on which threshold was crossed or reached	25,000,000			10.97%	227,881,315
Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ^ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
FI4000153309		25,000,000					10.97%


SUBTOTAL 8. A		25,000,000					10.97%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date ^x	Exercise/ Conversion Period ^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date ^x		Exercise/ Conversion Period ^xi		Physical or cash Settlement ^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii				x
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^xiv
Name ^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Faron Pharmaceuticals Ltd	10.97%		10.97%





10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information ^xvi
28.5.2026 Company announcement: Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company

Place of completion	Turku, Finland
Date of completion	11.6.2026

Faron Pharmaceuticals Ltd: Registration of Treasury Shares

11.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 11, 2026 at 17:00:00 EEST

Capitalised terms used in this announcement have the meanings given to them in the announcement made on 28 May 2026 at 15:35 EEST regarding the issue of treasury shares to the Company, unless the context provides otherwise.

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, as announced on 28 May 2026, issued 21,469,427 treasury shares to the Company itself without consideration to further prepare for any future conversions of the First and Second Tranche of Bonds.

In total, 21,469,427 new Treasury Shares in the Company have on 8 June 2026 been registered in the Finnish Trade Register. The treasury shares will rank pari passu in all respects with the existing shares of the Company. Following the registration of new Shares, the aggregate number of ordinary shares in the Company is 227,881,315 and of these shares, the Company holds 25,000,000 shares in treasury. The shares held in treasury by the Company do not confer a right to dividends or other shareholder rights.

The treasury shares will be listed on First North on 12 June 2026 and on AIM on or around 17 June 2026.

For more information, please contact:

IR Partners, Finland (Media) Kare Laukkanen	+358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

10.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 10, 2026 at 19:45:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)

1. Identity of the issuer: Faron Pharmaceuticals Oy
2. Reason for the notification (please tick the appropriate box or boxes): ☐ An acquisition or disposal of shares or voting rights ☒ An acquisition or disposal of financial instruments ☐ An event changing the breakdown of shares or voting rights ☐ Other (please specify): Click here to enter text.
3. Details of person subject to the notification obligation:
Name: Bank of America Corporation		City and country of residence: Wilmington, DE, United States of America
4. Full name of shareholder(s) (if different from 3.): –
5. Date on which the threshold was crossed or reached: 4.6.2026
6. Total positions of person(s) subject to the notification obligation:
	% of shares and voting rights (total of 7.A)		% of shares and voting rights through financial instruments (total of 7.B)	Total of both in % (7.A + 7.B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	0.11		10.46	10.57	206,411,888
Position of previous notification (if applicable)	0.10		9.36	9.46

7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of shares ISIN code (if possible)		Number of shares and voting rights				% of shares and voting rights
		Direct (SMA 9:5)		Indirect (SMA 9:6 and 9:7)		Direct (SMA 9:5)		Indirect (SMA 9:6 and 9:7)
FI4000153309		0		235,532		0		0.11
–		–		–		–		–
–		–		–		–		–
SUBTOTAL A		235,532				0.11

B: Financial Instruments according to SMA 9:6a
Type of financial instrument	Expiration date		Exercise/ Conversion Period		Physical or cash settlement		Number of shares and voting rights		% of shares and voting rights
Rights of Use	n/a		n/a		n/a		21,333,422		10.34
Swaps		15/10/2027		n/a	Cash		243,327		0.12
–	–		–		–		–		–
					SUBTOTAL B		21,576,749		10.46

8. Information in relation to the person subject to the notification obligation (please tick the applicable box): ☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. ☒ Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name	% of shares and voting rights	% of shares and voting rights through financial instruments	Total of both
Bank of America Corporation
NB Holdings Corporation
BofAML Jersey Holdings Limited
BofAML EMEA Holdings 2 Limited ML UK Capital Holdings Limited Merrill Lynch International Bank of America Corporation NB Holdings Corporation BAC North America Holding Company Bank of America, National Association Bank of America Corporation NB Holdings Corporation
Bofa Securities, Inc		10.34%	10.34%

9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of

10. Additional information:

Done at London, United Kingdom on 5.6.2026.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

8.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 08, 2026 at 19:30:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS

1a. Identity of the issuer or the underlying issuer of existing shares:			Faron Pharmaceuticals Oy
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer					X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of shares
An acquisition or disposal of financial instruments
An event changing the breakdown of shares outstanding					X
Other (please specify):
3. Details of person subject to the notification obligation
Name			Pentwater Capital Management LP
City and country of registered office (if applicable)			Naples, United States
4. Full name of shareholder(s) (if different from 3.)
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached:			04/06/2026
6. Date on which issuer notified (DD/MM/YYYY):			05/06/2026
7. Total positions of person(s) subject to the notification obligation
	% of shares outstanding (total of 8. A)	% of shares outstanding through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)		Total number of shares outstanding held in issuer
Resulting situation on the date on which threshold was crossed or reached		3.875746%		3.875746%		8,000,000.00
Position of previous notification (if applicable)		4.342441%		4.342441%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^v
A: Shares
Class/type of shares ISIN code (if possible)	Number of shares outstanding		% of shares outstanding
	Direct	Indirect	Direct	Indirect

SUBTOTAL 8. A

B 1: Financial Instruments as an entitlement to acquire
Type of financial instrument	Expiration date	Exercise/ Conversion Period	Number shares that may be acquired if the instrument is exercised/converted.	% of shares outstanding

		SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect
Type of financial instrument	Expiration date	Exercise/ Conversion Period	Physical or cash settlement	Number of shares	% of shares outstanding
Swap			Cash Settlement	8,000,000.00	3.875746%

			SUBTOTAL 8.B.2	8,000,000.00	3.875746%

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
Full chain of controlled undertakings through which the shares and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity(please add additional rows as necessary)				X
Name	% of shares outstanding if it equals or is higher than the notifiable threshold	% of shares outstanding through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Matthew Halbower
MCH PWCM Holdings Inc.
Pentwater Capital Management LP		3.875746%	3.875746%

10. Additional information

Place of completion	Naples
Date of completion	05/06/2026

Faron Pharmaceuticals Receives Decision from Nasdaq Helsinki Disciplinary Committee

5.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 05, 2026 at 13:50:00 EEST

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies, announces that, Nasdaq Helsinki Ltd’s Disciplinary Committee has issued their decision and imposed a fine amounting to EUR 30,000 on Faron Pharmaceuticals Oy (“Faron” or “Company”) for breaching the Nasdaq First North Growth Rulebook for Issuers of Shares (“Rules”) regarding the obligation to disclose inside information without undue delay in certain matters in 2024, and good securities market practise in connection with certain public statements made in a media interview in 2024.

The Disciplinary Committee dismissed two of the alleged breaches claimed by the market surveillance, importantly, an allegation that the Company’s administration was not organized in a manner required of a listed company. More details are available in a press release related to the decision published by Nasdaq Helsinki Ltd earlier today.

The Company notes that the cases under evaluation by the Disciplinary Committee were separate from each other and that the only reoccurring topic in the decision was the timing of announcements in AIM London and Nasdaq First North as the release hours are not the same in both markets. The Company notes that it has been listed in both markets since 2019 (in AIM London already since 2015), and it needs to secure simultaneous disclosure of information in both markets in accordance with relevant rules in order to be able to treat its shareholders equally. The Company has followed the same timing praxis to release announcements simultaneously that was established when the Company was listed in Helsinki First North back in 2019. As the Disciplinary Committee now ruled in its decision that disclosures must be done without delay irrespective of the possibility to publish simultaneously in London AIM, the Company will consider its options to fulfil this requirement in dialogue with the stock exchanges.

The Company aims in all of its operations to accurate, explicit and timely communication following all the rules the Company is obligated to follow. The Company takes compliance with the rules very seriously and continuously implements actions to ensure compliance. The fine does not have a material impact on the Company’s operations.

For more information, please contact:

IR Partners, Finland (Media) Kare Laukkanen	+358 50 553 9535 / +44 7 469 766 223 kare.laukkanen@irpartners.fi
FINN Partners, US (Media) Alyssa Paldo	+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	+44 (0) 207 213 0880
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	+358 (0)40 555 4727 +358 (0)50 553 8990

About Faron Pharmaceuticals Ltd

Forward-Looking Statements

Certain statements in this announcement are, or may be deemed to be, forward-looking statements. Forward looking statements are identified by their use of terms and phrases such as ”believe”, ”could”, “should”, “expect”, “hope”, “seek”, ”envisage”, ”estimate”, ”intend”, ”may”, ”plan”, ”potentially”, ”will” or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors’ current expectations and assumptions regarding the Company’s future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors’ current beliefs and assumptions and are based on information currently available to the Directors.

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully license its programs within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

4.6.2026

Faron Pharmaceuticals Ltd | Company announcement | June 04, 2026 at 15:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ⁱⁱ:			Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) ⁱⁱⁱ:
3. Details of person subject to the notification obligation ^iv
Name			Heights Capital Management, Inc.
City and country of registered office (if applicable)			San Francisco, California
4. Full name of shareholder(s) (if different from 3.) ^v
Name			CVI Investments, Inc.
City and country of registered office (if applicable)			Cayman Islands
5. Date on which the threshold was crossed or reached ^vi:			04/06/2026
6. Date on which issuer notified (DD/MM/YYYY):			04/06/2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) ^vii
Resulting situation on the date on which threshold was crossed or reached	10.33%	13.84%		24.17%	49,884,320
Position of previous notification (if applicable)	9.55%	15.44%		24.99%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached ^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ^ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
FI4000153309		21,324,320		28,560,000			10.33%		13.84%


SUBTOTAL 8. A		49,884,320					24.17%

B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date ^x	Exercise/ Conversion Period ^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights
Convertible Bond		08/02/2027	Anytime until maturity			11,760,000			5.7%
Convertible Bond		12/02/2028	Anytime until maturity			16,800,000			8.14%

			SUBTOTAL 8. B 1			28,560,000			13.84%

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date ^x		Exercise/ Conversion Period ^xi		Physical or cash Settlement ^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) ^xiv
Name ^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc.	10.33%	13.84%	24.17%
CVI Investments, Inc.	10.33%	13.84%	24.17%




10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information ^xvi
None

Place of completion	London, United Kingdom
Date of completion	04.06.2026